Sylvania Platinum (SLP) Competitors

Sylvania Platinum (LON:SLP) and Dr. Martens (LON:DOCS) are both small-cap computer software companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Do insiders and institutionals hold more shares of SLP or DOCS?

17.8% of Sylvania Platinum shares are held by institutional investors. Comparatively, 69.5% of Dr. Martens shares are held by institutional investors. 12.2% of Sylvania Platinum shares are held by company insiders. Comparatively, 4.4% of Dr. Martens shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is SLP or DOCS more profitable?

Sylvania Platinum has a net margin of 8.55% compared to Dr. Martens' net margin of 7.89%. Dr. Martens' return on equity of 18.91% beat Sylvania Platinum's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sylvania Platinum	8.55%	2.82%	1.69%
Dr. Martens	7.89%	18.91%	8.12%

Which has more volatility & risk, SLP or DOCS?

Sylvania Platinum has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Dr. Martens has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500.

Is SLP or DOCS a better dividend stock?

Sylvania Platinum pays an annual dividend of GBX 2 per share and has a dividend yield of 2.9%. Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 3.9%. Sylvania Platinum pays out 93.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Dr. Martens is clearly the better dividend stock, given its higher yield and lower payout ratio.

Do analysts rate SLP or DOCS?

Sylvania Platinum currently has a consensus target price of GBX 93, indicating a potential upside of 32.86%. Dr. Martens has a consensus target price of GBX 6,000, indicating a potential upside of 7,702.34%. Given Dr. Martens' higher possible upside, analysts clearly believe Dr. Martens is more favorable than Sylvania Platinum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sylvania Platinum	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dr. Martens	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has better valuation & earnings, SLP or DOCS?

Dr. Martens has higher revenue and earnings than Sylvania Platinum. Dr. Martens is trading at a lower price-to-earnings ratio than Sylvania Platinum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sylvania Platinum	£99.97M	2.26	£8.54M	£2.13	32.80
Dr. Martens	£874.20M	0.85	£68.97M	£7.05	10.90

Does the media prefer SLP or DOCS?

In the previous week, Sylvania Platinum had 2 more articles in the media than Dr. Martens. MarketBeat recorded 3 mentions for Sylvania Platinum and 1 mentions for Dr. Martens. Dr. Martens' average media sentiment score of 0.00 beat Sylvania Platinum's score of -0.36 indicating that Dr. Martens is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sylvania Platinum	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dr. Martens	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Dr. Martens beats Sylvania Platinum on 10 of the 18 factors compared between the two stocks.